Sectoral Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Sectoral Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-956	Closed	-$6.86K	–	78
2025 Q3	$6.86K	Sell	956 -14,152	-94%	-$738K	﹤0.01%	82
2025 Q2	$713K	Hold	15,108	–	–	0.47%	55
2025 Q1	$590K	Sell	15,108 -8,579	-36%	-$370K	0.46%	50
2024 Q4	$1.28M	Sell	23,687 -3,571	-13%	-$182K	0.86%	31
2024 Q3	$1.37M	Buy	27,258 +5,830	+27%	+$273K	0.81%	40
2024 Q2	$942K	Sell	21,428 -24,867	-54%	-$1.05M	0.38%	55
2024 Q1	$2.33M	Buy	46,295 +16,290	+54%	+$884K	0.91%	34
2023 Q4	$1.81M	Sell	30,005 -67,960	-69%	-$3.5M	0.78%	52
2023 Q3	$5.58M	Sell	97,965 -86,625	-47%	-$4.78M	1.09%	34
2023 Q2	$9.41M	Buy	+184,590	New	+$4.97M	1.57%	19

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sectoral Asset Management's MLTX Position: Q4 2025 in Review

Sectoral Asset Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 956 shares — an estimated $6.86K sold.

Sectoral Asset Management first reported a position in MLTX in Q2 2023 and held it in 10 quarters. The position peaked at $9.41M in Q2 2023. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

Sectoral Asset Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
Sectoral Asset Management sold 956 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $6.86K.
Sectoral Asset Management first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 10 quarters.
Sectoral Asset Management's MoonLake Immunotherapeutics position peaked at $9.41M in Q2 2023.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Sectoral Asset Management's 13F filing for Q4 2025, filed 9 Feb 2026.